Abstract：
Actinic keratosis (AK) is a common precancerous condition found on sun-damaged skin. Tirbanibulin 1 % ointment has been approved for the topical treatment of non-hyperkeratotic facial and scalp Olsen grade I AKs over a contiguous area of 25 cm2 with a daily application for 5 consecutive days. Our aim was to investigate the use of in vivo RCM in the assessment of the response of AKs treated with tirbanibulin, as it has never been described in the published Literature. A total of 10 AKs in 10 consecutive outpatients were enrolled in the present study in May 2023. The follow-up visit was scheduled after 30 days from last application of tirbanibulin ointment. At follow-up visit, a complete response was described by clinical, dermoscopic and in vivo RCM examination in 10 out of 10 lesions, with a recovery of stratum corneum, decrease in atypical honeycomb pattern and changes in dermal collagen. All patients were followed up for at least 8 months and further recurrences were not registered. Based on our experience, we confirm the efficacy and safety of tirbanibulin in treating AKs and the usefulness of RCM in vivo examination for the therapeutic monitoring of such lesions, even in a very early stage.
摘要：
光化性角化病（AK）是在阳光损伤的皮肤上发现的常见的癌前病变。Tirbanibulin1％软膏已被批准用于在25cm2的连续区域上局部治疗非过度角化面部和头皮OlsenI级AK，每天连续5天。我们的目的是研究体内RCM在评估用替尼布林治疗的AKs反应中的应用，这在出版的文献中从未描述过。2023年5月，本研究共纳入10例连续门诊患者中的10例AKs。从最后一次应用替巴尼布林软膏起30天后安排随访。在后续访问中，临床描述了完全的反应，10个病变中的10个的皮肤镜和体内RCM检查，随着角质层的恢复，非典型蜂窝状模式的减少和真皮胶原蛋白的变化。所有患者均随访至少8个月，未记录进一步复发。根据我们的经验,我们证实了替班尼布林治疗AKs的有效性和安全性，以及RCM体内检查对此类病变的治疗监测的有用性，即使在非常早期的阶段。
